FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action
This article was originally published in The Tan Sheet
Executive Summary
Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run
You may also be interested in...
States’ Limits On OTC Dextromethorphan Sales Could Force Congress’ Hand
US House legislation banning the sale of DXM OTCs to consumers under age 18 likely stands the same chance right now as previous versions that have failed, but CHPA expects an increasing number of state laws could spur future action.
States’ Limits On OTC Dextromethorphan Sales Could Force Congress’ Hand
US House legislation banning the sale of DXM OTCs to consumers under age 18 likely stands the same chance right now as previous versions that have failed, but CHPA expects an increasing number of state laws could spur future action.
US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years
A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.